Skip to content
Tuesday 1 September 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,789.28
-0.32%
DAX
25,970.11
-1.10%
CAC 40
8,301.85
-0.39%
STOXX 50
6,368.98
-0.80%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Friday 07 May 2021 4:33 pm

Two-thirds of UK adults given first dose of Covid-19 jab

By: James Warrington

Add as a preferred source on Google
Lord Mayor Of London Visits Fleet Street Vaccination Center
The UK is on track to offer a first dose of the vaccine to all UK adults by the end of July

Two-thirds of adults in the UK have now received their first dose of the Covid-19 jab as the rollout of the vaccine continues at pace.

A total of 35m people have now been given their first dose while a further 16.7m Brits have received their second.

The government met its target of fully vaccinating the most vulnerable by 15 April and is on track to offer a first dose to all adults by the end of July.

Data from a Public Health England study shows the vaccination programme has helped to significantly reduce hospitalisations and deaths.

In those over 70 both the Pfizer and Astrazeneca jabs reduce the risk of getting symptomatic disease by around 60 per cent after a single dose.

In those aged over 80, protection against hospitalisation is around 80 per cent and the Pfizer/ vaccine is 85 per cent effective at stopping people aged over 80 dying from Covid-19.

Data from the ONS and Oxford University shows that infections fell by 65 per cent after the first dose of the vaccines, rising further after the second dose.

Read more

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

The government this morning announced that people under the age of 40 will be offered an alternative to the Astrazeneca vaccine following concerns of rare blood clots.

It marks an extension of previous guidance, which stated under 30s should steer away from the Oxford vaccine.

However, the Joint Committee on Vaccination and Immunisation insisted that no new safety concerns have emerged over the Astrazeneca vaccine and that the recommendation amounted to “precautionary” advice.

Vaccines minister Nadhim Zahawi said reaching two-thirds of the adult population was an “incredible achievement”.

“It is now more important than ever to come forward for the second dose, so we can ensure everyone has the absolute strongest possible protection from this dreadful virus,” he said.

“I encourage everyone to book their jab as soon as they’re offered it, and to come back for their second dose. It’s never too late to come forward if you are eligible.”

Read more

Budget supermarket Iceland’s sneaky jab at Big Four management consultants

Iceland has reported its latest financial results.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus

Trending Articles

  • Vodafone and Deliveroo look to patch up Reform ties after Yusuf prison threats

  • Jaguar reveals the Type 01’s screen-free interior

  • Trio of firms poised to quit London Stock Exchange as exodus gathers pace

  • As it happened: FTSE 100 slides as bound rout deepens; Oil jumps as Trump vows more strikes on Iran

  • Green activists want to take Polanski down a dark road

More from Morning Wire

  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • Budget supermarket Iceland’s sneaky jab at Big Four management consultants

    Retail
    Iceland has reported its latest financial results.
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Fine dining and The Jab: A Michelin dinner with the Ozempic set

    Life&Style
    Ozempic tablet on a plate highlighting medications role in weight loss and diabetes management in healthcare news.
  • Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

    Business Wire
  • Scotch Malt Whisky Society’s Caskmaster 2026 championship comes to London

    Whisky
    The Scotch Malt Whisky Society was established in Edinburgh in 1983
  • ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

    Business Wire
  • Lamborghini Urus SE Performante is an even more super SUV

    Life&Style
    Lamborghini Urus luxury SUV in motion, showcasing sleek design and performance on a scenic road for a news feature
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook